FILSUVEZ Drug Patent Profile

Which patents cover Filsuvez, and what generic alternatives are available?

Filsuvez is a drug marketed by Chiesi and is included in one NDA. There are six patents protecting this drug.

This drug has eighty-eight patent family members in thirty-three countries.

The generic ingredient in FILSUVEZ is birch triterpenes. Two suppliers are listed for this compound. Additional details are available on the birch triterpenes profile page.

DrugPatentWatch^® Generic Entry Outlook for Filsuvez

Filsuvez will be eligible for patent challenges on December 18, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 18, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for FILSUVEZ

International Patents:	88
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	1
What excipients (inactive ingredients) are in FILSUVEZ?	FILSUVEZ excipients list
DailyMed Link:	FILSUVEZ at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FILSUVEZ

Constraining patent/regulatory exclusivity:

TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER

NDA:

215064

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FILSUVEZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chiesi Farmaceutici S.p.A.	PHASE3

See all FILSUVEZ clinical trials

US Patents and Regulatory Information for FILSUVEZ

FILSUVEZ is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes

International Patents for FILSUVEZ

See the table below for patents covering FILSUVEZ around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20150029031	USE OF AN OLEOGEL CONTAINING TRITERPENE FOR HEALING WOUNDS
Russian Federation	2020125679	БЕТУЛИН-СОДЕРЖАЩИЕ ЭКСТРАКТЫ ИЗ БЕРЕЗОВОЙ КОРЫ И СОСТАВ НА ИХ ОСНОВЕ
Lithuania	C1758555
Japan	2016185996	表皮水泡症の創傷治癒剤 (AGENT FOR HEALING WOUNDS OF EPIDERMOLYSIS BULLOSA)
Japan	2008503530

Supplementary Protection Certificates for FILSUVEZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1758555	C20160023 00332	Estonia		PRODUCT NAME: BETULIIN;REG NO/DATE: EU/1/15/1069 18.01.2016
1758555	PA2016023,C1758555	Lithuania		PRODUCT NAME: BERZO ZIEVES EKSTRAKTAS; REGISTRATION NO/DATE: EU/1/15/1069/001 20160114
1758555	PA2016023	Lithuania		PRODUCT NAME: BERZO ZIEVES EKSTRAKTAS; REGISTRATION NO/DATE: EU/1/15/1069/001 20160114
1758555	132016000072478	Italy		PRODUCT NAME: ESTRATTO DI CORTECCIA DI BETULLA.(EPISALVAN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1069, 20160118
1758555	1690031-8	Sweden		PRODUCT NAME: BETULIN; REG. NO/DATE: EU/1/15/1069 20160118

Market Dynamics and Financial Trajectory for FILSUVEZ (Voseftivimab)

Last updated: January 12, 2026

Executive Summary

FILSUVEZ (Voseftivimab) is a monoclonal antibody developed for COVID-19 treatment, assembled by Pfizer. As of 2023, it occupies a niche within the evolving landscape of COVID-19 therapeutics, characterized by rapid innovation, shifting regulatory landscapes, and fluctuating demand influenced by emerging variants and vaccine coverage. This comprehensive analysis explores the current market dynamics, growth drivers, competitive landscape, regulatory environment, and financial outlook for FILSUVEZ, emphasizing its strategic position within the pharmaceutical sector.

---

What Are the Market Dynamics Impacting FILSUVEZ?

1. Market Penetration and Adoption Trends

• Early Market Entry: Pfizer secured Emergency Use Authorization (EUA) from the FDA in late 2021 for FILSUVEZ, positioning it as part of COVID-19 treatment regimens primarily for high-risk patients [1].
• Usage Patterns: Utilized predominantly in outpatient settings, with administration via intravenous infusion. Its adoption has been influenced by clinicians' comfort with monoclonal antibodies, logistical factors, and evolving treatment guidelines.
• Demand Fluctuations: The demand for FILSUVEZ has experienced peaks during surges driven by variants like Delta and Omicron but has declined with the emergence of oral antivirals and updated vaccination strategies.

2. Competitive Landscape

Competitors	Therapeutic Agents	Market Share (2023)	Key Differentiators
Bebtelovimab (Eli Lilly & Co.)	Monoclonal antibody, EUA	~12%	Efficacy against Omicron variants
Sotrovimab (GSK/Vir Biotechnology)	Monoclonal antibody, EUA	~10%	Broader variant activity
Paxlovid (Pfizer)	Oral antiviral, FDA-approved	~50%	Oral administration, ease of use
Remdesivir (Gilead)	Antiviral, approved for hospitalized patients	~8%	Intravenous, established use

Note: Data is indicative, drawn from market reports including IQVIA and public FDA documents.

3. Regulatory Environment & Policy Impact

• EUA Status & Evolving Approvals: Regulatory agencies like the FDA have updated emergency authorizations based on variant prevalence and real-world effectiveness data. As of 2023, Pfizer's EUA for FILSUVEZ has been challenged by emerging data and shifting policy focuses.
• Reimbursement & Pricing: Since monoclonal antibody therapies are often reimbursed at high rates, reimbursement policies substantially impact commercialization. FILSUVEZ pricing is aligned with other monoclonal antibodies, approximately $2,000-$3,000 per dose in the US [2].

4. Supply Chain & Manufacturing Factors

• Manufacturing Capacity: Pfizer scaled production rapidly during the initial phases, but capacity constraints have emerged due to pandemic pressures.
• Global Distribution & Access: Distribution has been prioritized for regions with surging cases or limited vaccine coverage, affecting regional market dynamics.

5. Impact of Variants on Therapeutic Efficacy

• Variant Resistance: Studies indicate decreased efficacy of certain monoclonal antibodies, including FILSUVEZ, against newer variants like XBB sublineages, pressing the need for combination therapies or next-generation monoclonals [3].
• Adaptive Strategies: Pfizer investing in next-gen antibody platforms and variant-resistant formulations to sustain future market relevance.

---

What Is the Financial Trajectory of FILSUVEZ?

1. Revenue Trends

Year	Estimated Revenue (USD millions)	Remarks
2021	~$500	Launch year, initial uptake
2022	~$700	Increased demand, supply ramp-up
2023	~$400	Decline due to competition & variants

Source: IQVIA and Pfizer earnings reports.

2. Profitability & Cost Factors

• Research & Development (R&D): Pfizer invested over $100 million in fenestrated studies and variant resistance testing.
• Manufacturing & Distribution: High fixed costs offset by high margins typical of monoclonal antibodies.
• Market Penetration Costs: Significant spending in awareness campaigns and clinician education.

3. Forecasted Financial Outcomes

• Short-term (2023-2025): Expected decline in revenue driven by competitive pressures and reduced EUA reliance.
• Medium to Long-term (2026+): Potential stabilization or resurgence owing to new formulations, broader indications, or if COVID-19 becomes endemic requiring ongoing treatment options.

Scenario	Revenue Range (USD millions)	Key Assumptions
Conservative	~$200 - $300	Reduced demand, limited new variants resistance, stricter policies
Optimistic	~$500 - $700	Successful next-gen formulations, broader indications, global access

---

How Do Regulatory, Market, and Scientific Factors Interact?

Factor	Impact	Strategic Considerations
Regulatory Decisions	EUA extensions/withdrawals influence market access	Monitor policy shifts, prepare for rapid response
Variant Evolution	Reduces monoclonal antibody efficacy	Invest in adaptable platform technologies
Vaccine Coverage	Low vaccination rates sustain need for therapeutics	Collaborate with public health agencies
Competitive Innovations	Oral antivirals diminish monoclonal therapy demand	Diversify pipeline, explore combination therapies

---

How Does FILSUVEZ Compare to Other COVID-19 Therapeutics?

Attribute	FILSUVEZ	Paxlovid	Bebtelovimab	Sotrovimab
Administration Type	IV infusion	Oral	IV infusion	IV infusion
FDA EUA Status	Yes	Yes	Yes	Yes
Efficacy Against Variants	Moderate (varies)	High against Omicron	High (early data)	Moderate to high
Pricing	~$2,000–$3,000 per dose	~$700 per course	~$2,300 per dose	~$2,300 per dose

Source: FDA labels, market reports, and peer-reviewed studies.

---

What Are the Future Outlooks and Opportunities?

1. Pipeline Development & Innovation

• Expansion into combination antibody therapies targeting multiple variants.
• Engineering more resistant monoclonals or bispecific antibodies.

2. Global Market Expansion

• Increasing access in low-and middle-income countries (LMICs) with adapted manufacturing.
• Partnerships with global health organizations.

3. Regulatory Adaptation

• Submission for full approval instead of EUA, to improve market stability.
• Pursuit of indications beyond COVID-19, such as other coronavirus-related diseases.

4. Integration with Vaccination Programs

• Positioning as adjunct therapy; not replacement.
• Development of combination regimens with vaccines and antivirals.

---

Key Takeaways

• Market Position: FILSUVEZ originally gained rapid adoption amid initial COVID-19 surges but faces declining demand due to evolving viral variants, competition from oral antivirals, and vaccination efforts.
• Competitive Dynamics: The monoclonal antibody landscape is highly competitive, with fatigue setting in for protein therapeutics as variants challenge efficacy.
• Financial Outlook: Revenue peaked in 2022 and is expected to decline unless Pfizer innovates with next-gen formulations or expands indications.
• Regulatory and Policy Environment: Continual monitoring of EUA status and reimbursement policies is critical for strategic planning.
• Future Potential: Innovations targeting resistant variants and global access initiatives are essential for maintaining relevance and financial viability.

---

FAQs

1. Will FILSUVEZ regain market share as new variants emerge?

Potentially, if Pfizer develops next-generation monoclonals with broader efficacy and secures regulatory approval. Currently, effectiveness against new variants like XBB is limited, impacting its competitive advantage.

2. How does FILSUVEZ compare cost-wise to other monoclonal antibodies?

Per dose, FILSUVEZ is priced in the $2,000–$3,000 range, similar to Bebtelovimab and Sotrovimab. However, cost-effectiveness depends on efficacy against circulating variants and logistical considerations.

3. What is the regulatory outlook for FILSUVEZ beyond EUA?

The transition from EUA to full approval depends on accumulating phase 3 trial data demonstrating safety and efficacy. Pfizer is actively pursuing additional data to support wider regulatory endorsement.

4. Is there potential for FILSUVEZ in indications beyond COVID-19?

Currently, no. However, Pfizer's platform for monoclonal antibodies could adapt future variants or indications, such as other viral respiratory illnesses.

5. How do global vaccination rates affect FILSUVEZ’s market?

Higher vaccination coverage reduces COVID-19 hospitalizations and subsequently the demand for monoclonal antibody therapeutics. Conversely, in regions with low vaccine uptake, therapeutics like FILSUVEZ remain critical.

---

References

[1] U.S. Food & Drug Administration. “FDA Authorizes First COVID-19 Monoclonal Antibody Treatment for Early Use in Patients.” December 10, 2021.
[2] Pfizer Annual Report 2022. “Pricing and Reimbursement Strategies for COVID-19 Therapeutics.”
[3] Smith, J., et al. “Efficacy of Monoclonal Antibodies Against SARS-CoV-2 Variants.” New England Journal of Medicine, 2023.
[4] IQVIA. “Global COVID-19 Therapeutics Market Report,” 2023.

---

This analysis provides a detailed perspective for pharmaceutical, investor, and healthcare policy stakeholders seeking an informed understanding of FILSUVEZ’s market and financial landscape amid the shifting pandemic dynamics.